Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Non-Current Liabilities (2020 - 2025)

Apellis Pharmaceuticals has reported Total Non-Current Liabilities over the past 6 years, most recently at $697.2 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $697.2 million for Q4 2025, up 7.5% from a year ago — trailing twelve months through Dec 2025 was $697.2 million (up 7.5% YoY), and the annual figure for FY2025 was $697.2 million, up 7.5%.
  • Total Non-Current Liabilities for Q4 2025 was $697.2 million at Apellis Pharmaceuticals, up from $654.3 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for APLS hit a ceiling of $697.2 million in Q4 2025 and a floor of $302.0 million in Q3 2021.
  • Median Total Non-Current Liabilities over the past 5 years was $591.9 million (2023), compared with a mean of $583.0 million.
  • Peak annual rise in Total Non-Current Liabilities hit 136.93% in 2021, while the deepest fall reached 32.73% in 2021.
  • Apellis Pharmaceuticals' Total Non-Current Liabilities stood at $338.0 million in 2021, then soared by 66.75% to $563.5 million in 2022, then increased by 5.03% to $591.9 million in 2023, then rose by 9.57% to $648.5 million in 2024, then increased by 7.5% to $697.2 million in 2025.
  • The last three reported values for Total Non-Current Liabilities were $697.2 million (Q4 2025), $654.3 million (Q3 2025), and $663.0 million (Q2 2025) per Business Quant data.